Phase 4 N=1 Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations
Cystic Fibrosis
Primary: Lung Function — 35 Liters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=936 Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye
Wet Age Related Macular Degeneration
Primary: Number of Participants With Systemic Drug-related Adverse Events — 3; 0 participants
Phase 4 N=46 PrOD for Non-Cirrhotic Patients With HCV-1b Receiving Hemodialysis
Hepatitis Viruses
Primary: Number of Participants With Sustained Virologic Response (SVR12) — 46 Participants
Phase 4 N=293 Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on Hemodialysis
Iron Deficiency Anemia Treatment · Chronic Kidney Disease(CKD)
Primary: Hemoglobin Changes — 0.5; 0.4; 0.6; 0.3 g/dL — p=<0.05
Phase 4 N=56 Mechanisms of Lipodystrophy in HIV-Infected Pateints
HIV Infections
Primary: Effect of Drug Regimens on Serum Triglycerides. — 228.0; 230.4; 293.4; 290.0 mg/dL — p=0.94
Phase 4 N=208 Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness
Relapsing-Remitting Multiple Sclerosis
Primary: Number of Participants With Adverse Events (AEs) — 107; 100; 44; 38 participants
Phase 4 N=188 Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)
Rhinitis, Allergic, Seasonal · Asthma
Primary: Change From Baseline in Morning (AM) and Evening (PM) Total Asthma Symptom Severity (TASS) — 6.5; 5.9; -0.9; -1.4 Score on a scale — p=0.101
Phase 4 N=387 A Trial to Compare the Duration of Analgesic Efficacy and Safety of Naproxen Sodium Tablets and Ibuprofen Tablets in Postsurgical Dental Pain
Pain, Postoperative
Primary: Time to First Use of Rescue Medication — 1.22; 1.22; 1.18; 11.017 hours — p=<0.001
Phase 4 N=79 Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Capsulotomy
Posterior Capsule Opacification · Ocular Hypertension
Primary: Intraocular Pressure (IOP) at 1 Hour After Nd-YAG Posterior Capsulotomy — 15.6; 15.7; 15.2; 13.7 mmHg — p=<0.05
Phase 4 N=114 Propofol and Dexmedetomidine Versus a Propofol Only Regimen for Sedation During Colonoscopy
Colonoscopy
Primary: Percentage of Subjects Ready for Discharge in Each Group at 30 Minutes Post Procedure — 26; 44 Participants
Phase 4 N=12,000 A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
Cardiovascular Disease · High Cardiovascular Risk · Obesity
Primary: Time From Randomization to First Occurrence of Major Adverse Cardiovascular Events (MACE) at Interim Analysis — NA; NA days — p=0.0001
Phase 4 N=2,425 A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 24 — 0.122; 0.056; -0.019 Liters — p=<0.001
Phase 4 N=420 Efficacy of Co-administration of Bilastine and Montelukast in Patients With SARC and Asthma
Seasonal Allergic Rhinoconjunctivitis · Asthma
Primary: Change From Baseline With Montelukast+Bilastine Compared With Bilastine Monotherapy in SARC Symptoms — -3.2522; -3.4462 score on a scale — p=0.5721
Phase 4 N=569 Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children
Influenza and Acute Respiratory Viral Infections
Primary: Average Illness Duration — 4.6; 4.9 days — p=0.0242
Phase 4 N=35 Evaluation of Skin Affix in the Emergency Room
Wounds
Primary: Wound Closure at Discharge — 100 percent of participants